Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06446648 · ClinicalTrials.gov registry record · Early Phase 1
Impact of Intraoperative ICG on Functional Outc in RARP
A Early Phase 1 study of Prostate Adenocarcinoma, sponsored by University of California, Irvine.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 400
- Enrollment target
- 1
- Study location
NCT06446648 is a Early Phase 1 study of Prostate Adenocarcinoma that is actively recruiting participants, run by University of California, Irvine. The registered enrollment target is 400 participants, above the 214-participant average among 99 other Prostate Adenocarcinoma trials with a reported enrollment target (87% higher). The trial reports 1 study location across 1 state.
The verdict
NCT06446648, a Early Phase 1 study of Prostate Adenocarcinoma, is actively recruiting participants, sponsored by University of California, Irvine.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 400 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a pilot, 3 phases open-label feasibility study with the 3rd phase consisting of randomized 2-arm intervention trial, to assess the systematic use of indocyanine green (ICG) in subjects with prostate adenocarcinoma during robot-assisted radical prostatectomy and its impact on sexual function outcomes at 12 months postoperatively.
Conditions Studied
Interventions
- DRUG ICG
Study Locations (1)
California
- Chao Family Comprehensive Cancer Center University of California, Irvine - Orange
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2024-07-12 |
| Est. Completion | 2030-07 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06446648
The ClinicalTrials.gov registry entry for NCT06446648 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 214-participant average among 99 other Prostate Adenocarcinoma trials with a reported enrollment target (87% higher). The listed sponsor is University of California, Irvine, which has 368 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which ICG is the first listed.
NCT06446648 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06446648 about?
NCT06446648 is a clinical study titled "Impact of Intraoperative ICG on Functional Outc in RARP". This is a pilot, 3 phases open-label feasibility study with the 3rd phase consisting of randomized 2-arm intervention trial, to assess the systematic use of indocyanine green (ICG) in subjects with prostate adenocarcinoma during robot-assisted radical prostatectomy and its impact on sexual function ...
What is the current status of trial NCT06446648?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 400 participants. The study started on 2024-07-12. Estimated completion is 2030-07.
What conditions does trial NCT06446648 study?
This clinical trial studies the following conditions: Prostate Adenocarcinoma.
What interventions are being tested in trial NCT06446648?
The interventions under investigation include: ICG (DRUG).
Who is sponsoring clinical trial NCT06446648?
This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06446648 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
rhPSMA-73 PET-MRI Imaging for the Detection of Prostate Cancer Among Men Who Are Otherwise Candidates for Active Surveillance
RECRUITING · Early Phase 1
-
An Investigational Scan (rhPSMA-7.3 PET/CT) for Detecting Biochemically Recurrent Prostate Cancer, ENLIGHTEN Trial
RECRUITING · Early Phase 1
-
Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression
ACTIVE NOT RECRUITING · Early Phase 1
-
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
RECRUITING · Phase 3
-
MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy
RECRUITING · NA
-
Customized TULSA-PRO Ablation Registry
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.